Ginger: From the Roots to the Rhythm

Cardiovascular diseases (CVDs) remain the leading cause of global mortality despite advances in pharmacotherapy. Interest in nutraceuticals with multitarget mechanisms has intensified, particularly those supported by both traditional medicine and modern molecular evidence. Zingiber officinale (ginger) has a long history of use in Ayurvedic and traditional medical systems and is increasingly supported by experimental and clinical research. This review integrates pharmacognostic, phytochemical, molecular, and clinical evidence, with special emphasis on the detailed mechanisms of action of gingerols and shogaols. Mechanistic insights derived from recent signaling‑pathway–focused studies are incorporated into an existing cardiovascular review framework. Ginger exerts cardioprotective effects through antioxidant, anti‑inflammatory, antihypertensive, antihyperlipidemic, antiplatelet, and metabolic regulatory pathways involving Nrf2/ARE, NF‑κB, MAPK, AMPK, PI3K/Akt, eNOS, COX, and PPAR signaling. Human trials and meta‑analyses demonstrate modest but clinically relevant reductions in blood pressure, lipids, glycemia, and inflammatory markers. Collectively, ginger represents a safe, low‑cost adjunctive strategy for cardiovascular prevention and risk reduction, although long‑term standardized trials with hard endpoints remain necessary.